Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Phase 1 Clinical Trial to Establish an RG-A/Texas/71/2017 (H3N2) Influenza Controlled Human Infection Model (CHIM) That Safely and Reproducibly Induces Symptomatic Influenza Virus Infection in Healthy Adults 18-45 Years of Age After Intranasal Challenge

NCT07305207 is registered in ClinicalTrials.gov with Dalhousie University as lead sponsor.

NCT NCT07305207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07305207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Phase 1 Clinical Trial to Establish an RG-A/Texas/71/2017 (H3N2) Influenza Controlled Human Infection Model (CHIM) That Safely and Reproducibly Induces Symptomatic Influenza Virus Infection in Healthy Adults 18-45 Years of Age After Intranasal Challenge
Lead sponsor
Dalhousie University
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2026
Completion date
January 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza (healthy volunteers)